Compare IDEXX Laboratories, Inc. (IDXX) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while JPMorgan Ultra Short Income ETF trades at $50.47. Which is the better fit depends on your goals.
| IDXX | JPST | |
|---|---|---|
Market Cap | $46.22B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $766.68 | $50.78 |
52-Week Low | $526.44 | $50.40 |
Enterprise Value | $47.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
JPST (JPMorgan Ultra-Short Income ETF) trades at $50.46, showing minimal daily movement with a 0.04% gain. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent institutional filings show growing interest, with Financial Management Professionals increasing their stake by 4.7% in Q2 2026. The fund provides regular dividend distributions, with recent payments of $0.17 per share.
As an ultra-short income ETF, JPST offers stability and income generation in a rising rate environment. The fund's conservative positioning appeals to risk-averse investors seeking cash alternatives. Key risks include interest rate sensitivity and inflationary pressures that could impact short-term bond yields. Institutional accumulation suggests confidence in the fund's strategic positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
